Xenon Pharmaceuticals Inc. (XENE)

NASDAQ: XENE · IEX Real-Time Price · USD
37.17
+1.13 (3.14%)
Oct 4, 2022 12:10 PM EDT - Market open
3.14%
Market Cap 2.31B
Revenue (ttm) 21.16M
Net Income (ttm) -90.69M
Shares Out 62.26M
EPS (ttm) -1.56
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 164,425
Open 36.75
Previous Close 36.04
Day's Range 36.75 - 38.41
52-Week Range 23.26 - 41.39
Beta 1.47
Analysts Buy
Price Target 51.56 (+38.7%)
Earnings Date Nov 8, 2022

About XENE

Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, A Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epilepsy encephalopathy; and XEN1101, A Kv7 potassium channel opener, which is in Phase II clinical trial for the treatment of epilepsy and other neurological disorders. The company's product candidates also comprise NBI-9213... [Read more...]

Industry Biotechnology
IPO Date Nov 5, 2014
CEO Simon Pimstone
Employees 149
Stock Exchange NASDAQ
Ticker Symbol XENE
Full Company Profile

Financial Performance

In 2021, XENE's revenue was $18.44 million, a decrease of -42.68% compared to the previous year's $32.17 million. Losses were -$78.88 million, 173.5% more than in 2020.

Financial Statements

Analyst Forecast

According to 18 analysts, the average rating for XENE stock is "Buy." The 12-month stock price forecast is 51.56, which is an increase of 38.71% from the latest price.

Price Target
$51.56
(38.71% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Xenon Pharmaceuticals to Present at the Wells Fargo 2022 Healthcare Conference

BURNABY, British Columbia, Sept. 01, 2022 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that management will participate in...

1 month ago - GlobeNewsWire

Xenon Pharmaceuticals (XENE) Reports Q2 Loss, Misses Revenue Estimates

Xenon Pharmaceuticals (XENE) delivered earnings and revenue surprises of -12.25% and 91.63%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

1 month ago - Zacks Investment Research

Xenon Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update

Xenon remains on track to initiate the XEN1101 Phase 3 program within second half of this year

1 month ago - GlobeNewsWire

Xenon Pharmaceuticals Announces Conference Call and Webcast to Discuss Second Quarter 2022 Financial Results and Prov...

BURNABY, British Columbia, Aug. 02, 2022 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced it will report its second quarter 20...

2 months ago - GlobeNewsWire

Xenon Pharmaceuticals to Present at the William Blair Biotech Focus Conference 2022

BURNABY, British Columbia, July 11, 2022 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that management will participate in ...

2 months ago - GlobeNewsWire

Xenon Pharmaceuticals Announces Closing of $287.5 Million Public Offering Including Full Exercise of the Underwriters...

BURNABY, British Columbia, June 27, 2022 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical stage biopharmaceutical company, today announced the closing of its previously announced...

3 months ago - GlobeNewsWire

Xenon's Epilepsy Candidate Rapidly Reduces Focal Onset Seizure Frequency

Xenon Pharmaceuticals Inc (NASDAQ: XENE) announced new efficacy data supporting the Phase 3 development of XEN1101. XEN1101 rapidly reduced focal onset seizure frequency within one week for all doses co...

3 months ago - Benzinga

Xenon Pharmaceuticals Announces Pricing of $250.0 Million Public Offering

BURNABY, British Columbia, June 22, 2022 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical stage biopharmaceutical company, today announced the pricing of its underwritten public ...

3 months ago - GlobeNewsWire

Xenon Pharmaceuticals Shares Drop On Proposed Public Offering

Xenon Pharmaceuticals Inc (NASDAQ: XENE) announced an underwritten public offering of its common shares. Underwriters of the offering will be granted an option for a period of 30 days to purchase an add...

3 months ago - Benzinga

Xenon Pharmaceuticals Announces Proposed Public Offering

BURNABY, British Columbia, June 22, 2022 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a clinical stage biopharmaceutical company, today announced that it has commenced an underwritten ...

3 months ago - GlobeNewsWire

Xenon Pharmaceuticals Provides Update on Additional Positive Data from the XEN1101 Program

New XEN1101 Phase 2b X-TOLE sub-group analysis demonstrates statistically significant efficacy results at all doses at Week 1, differentiating XEN1101 with rapid onset to seizure reduction

3 months ago - GlobeNewsWire

Xenon Pharmaceuticals Announces Positive Outcome of End-of-Phase 2 Meeting with the FDA

XEN1101 Phase 3 program for the treatment of focal onset seizures to be initiated in the second half of 2022 and New Drug Application expected to be submitted after completion of first Phase 3 clinical ...

3 months ago - GlobeNewsWire

Xenon Pharmaceuticals to Present at the 2022 Jefferies Healthcare Conference

BURNABY, British Columbia, June 01, 2022 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that management will participate in ...

4 months ago - GlobeNewsWire

Xenon Pharmaceuticals (XENE) Reports Q1 Loss, Misses Revenue Estimates

Xenon Pharmaceuticals (XENE) delivered earnings and revenue surprises of 7.89% and 4.92%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

4 months ago - Zacks Investment Research

Xenon Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update

XEN1101 “End of Phase 2” Meeting with FDA to take Place in Second Quarter and Initiation of Phase 3 in Adult Focal Epilepsy Expected in the Second Half of 2022

4 months ago - GlobeNewsWire

Xenon Pharmaceuticals Announces Conference Call and Webcast to Discuss First Quarter 2022 Financial Results and Provi...

BURNABY, British Columbia, May 03, 2022 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced it will report its first quarter 2022...

5 months ago - GlobeNewsWire

Xenon Pharmaceuticals to Participate in Upcoming Investor Conferences

BURNABY, British Columbia, April 25, 2022 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company today announced that Xenon's management team will pa...

5 months ago - GlobeNewsWire

Xenon Pharmaceuticals to Present at the 21st Annual Needham Virtual Healthcare Conference

BURNABY, British Columbia, April 04, 2022 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that management will participate in...

5 months ago - GlobeNewsWire

Xenon Pharmaceuticals to Present at Stifel 2022 CNS Days

BURNABY, British Columbia, March 22, 2022 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that management will participate in...

6 months ago - GlobeNewsWire

Xenon Pharmaceuticals (XENE) Reports Q4 Loss, Lags Revenue Estimates

Xenon Pharmaceuticals (XENE) delivered earnings and revenue surprises of -21.28% and 11.02%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

7 months ago - Zacks Investment Research

Xenon Pharmaceuticals Reports 2021 Financial Results and Provides Corporate Update

Conference Call at 4:30 pm ET Today Conference Call at 4:30 pm ET Today

7 months ago - GlobeNewsWire

Xenon Pharmaceuticals Announces Conference Call and Webcast to Discuss Year-End 2021 Financial Results and Provide Co...

BURNABY, British Columbia, Feb. 22, 2022 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced it will report its financial results...

7 months ago - GlobeNewsWire

Xenon Pharmaceuticals to Participate in the 11th Annual SVB Leerink Global Healthcare Conference

BURNABY, British Columbia, Feb. 14, 2022 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced its participation in one-on-one inve...

7 months ago - GlobeNewsWire

Xenon Receives $15M Regulatory Milestone Under Epilepsy Pact With Neurocrine

Xenon Pharmaceuticals Inc's (NASDAQ: XENE) collaboration to develop treatments for epilepsy with Neurocrine Biosciences Inc (NASDAQ: NBIX) achieved a regulatory milestone, triggering a payment of $15.0 ...

Other symbols: NBIX
8 months ago - Benzinga

Xenon Pharmaceuticals Announces Collaboration with Neurocrine Biosciences Achieves $15.0 Million Regulatory Milestone

BURNABY, British Columbia, Jan. 12, 2022 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that its collaboration to develop tr...

8 months ago - GlobeNewsWire